Health Insurer Earnings Show Margin Relief, Medicaid Pressure, and Medicare Momentum
Health insurers entered the final stretch of 2026 with a quarter that looked better than the one that started the year, even as medical cost trend remained a stubborn pressure point. The biggest publicly traded payers largely posted stronger profits, and several executives pointed to improving signs in government lines of business, especially Medicaid and Medicare Advantage.
UnitedHealth Group remained the most profitable payer in the period, posting $4.1 billion in profit for Q3, up from $2.3 billion in the prior-year quarter. Through the first nine months of the year, the company generated $15.9 billion in profit, compared with $12 billion a year earlier. Revenue reached $112.7 billion, a slight decline from $113.2 billion in the third quarter of 2025.
The improvement matters because UnitedHealth has spent much of the past year in financial repair mode. The company has described that turnaround as especially important at Optum Health, which had been one of the major pressure points when the group delivered an unusually weak quarter to start 2025. Patrick Conway, M.D., who leads Optum, framed the recovery around a return to value-based care principles. In payer economics, that shift is not just a slogan: when care is organized around risk-bearing relationships and longitudinal patient management, utilization can be steered away from fragmented, high-cost episodes and toward better coordinated outpatient care.
One sentence captures the broader tone of the quarter: UnitedHealth’s profitability rebounded while revenue held essentially steady.
CVS Health delivered the second-largest profit and revenue haul in Q3, earning $2.2 billion after a nearly $4 billion loss in the same quarter last year. Revenue climbed to $108.4 billion from $102.9 billion. The company’s earnings improvement came against the backdrop of one of the most consequential corporate restructurings in the sector, with CVS announcing plans to split its pharmacy business into a separate company while Aetna and Caremark remain together under CVS Health. The separation is slated to close in the first half of 2028.
For a business built around overlapping roles in insurance, pharmacy benefit management, and retail pharmacy, the breakup signals a strategic attempt to reduce complexity and sharpen investor focus. CEO David Joyner said the structure is intended to support long-term value creation. In clinical terms, that corporate architecture affects how patients encounter the system: pharmacy access, drug affordability, and coverage administration often flow through the same payer ecosystem, so a split could alter how those functions are managed even if the medical benefit remains under the same umbrella.
Cigna Group and Elevance Health landed close together on profit, each reporting $1.4 billion in Q3 earnings. Cigna produced more revenue, posting $73.7 billion versus Elevance’s $51.4 billion. Cigna’s profit declined from $1.9 billion a year earlier, though revenue rose from $69.7 billion in Q3 2025.
Cigna’s management centered its quarterly narrative on the newly unveiled Lead to One strategy, which is designed to create a more personalized experience for members and customers. The company said it will lean on its full set of business segments to better match offerings to individual needs. For a national insurer with a broad portfolio, the operating challenge is straightforward but difficult: align benefits, pharmacy services, and care navigation closely enough that members experience one connected system rather than several disconnected ones.
Elevance posted a modest year-over-year profit increase from $1.2 billion in Q3 2025. Leaders said Medicaid remains a rough patch, but not an irreversible one. The company still views 2026 as a trough year for Medicaid performance, with improvement expected in 2027 as state rate setting catches up to rising care costs and the higher acuity of enrolled populations. State Medicaid programs have been adjusting payments more fully to reflect the medical complexity of members, and executives also pointed to work requirements beginning this year as a factor likely to increase acuity in the remaining membership mix.
One practical consequence is already visible in the pricing math. When rates more accurately reflect utilization and illness burden, insurers have less need to absorb losses created by underpriced contracts. The flip side is that the stability can take time to show up in earnings.
Centene’s quarter told a similar story, though from a lower base. The company posted a $71 million loss, a dramatic improvement from a $6.6 billion loss in the prior-year quarter, when the result was distorted by a one-time impairment charge of more than $6 billion. Revenue edged up to $50.6 billion from $49.7 billion a year earlier. CEO Sarah London said Medicaid still offers long-term growth potential and pointed again to state rate setting as a supportive force. She also said the insurer has made meaningful progress in behavioral health, one of the most clinically important and cost-sensitive areas in managed care.
That matters because behavioral health is one of the clearest examples of how payer economics and clinical need intersect. Untreated depression, anxiety, substance use disorder, and other behavioral conditions can drive emergency department use, poor medication adherence, and avoidable medical spending across the system. Improvements there can affect both outcomes and margins.
Humana rounded out the quarter with a smaller profit than a year ago, reporting $162 million compared with $195 million in Q3 2025. Revenue rose sharply to $41.15 billion from $32.6 billion, and early signals from the annual Medicare enrollment period point to additional Medicare Advantage membership growth in 2027. CEO Jim Rechtin said early sign-ups suggest the company is gaining traction, helped by new enrollments and recapturing members affected by market exits.
The Medicare Advantage business remains a central battleground for the industry because enrollment, plan design, and retention directly shape future premium revenue. Early enrollment trends do not guarantee the final outcome, but they do influence how insurers plan benefit bids, network strategies, and medical cost assumptions for the next year. For Humana, the early readout was encouraging enough to suggest momentum may persist into the next cycle.
Across the sector, the quarter exposed a common pattern: higher or stabilizing profits, improving government-program signals, and continued dependence on tighter care management to control medical expense. The central unresolved issue is how durable those gains will be once rate changes, utilization shifts, and membership mix changes are fully absorbed in 2027.